Lack of dopamine D4 receptor affinity contributes to the procognitive effect of lurasidone

Behavioural Brain Research

Volumn 261, Issue , 2014, Pages 26-30

  Murai, Takeshi ^a   Nakako, Tomokazu ^a   Ikeda, Kazuhito ^a   Ikejiri, Masaru ^a   Ishiyama, Takeo ^a   Taiji, Mutsuo ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Cognition; Common marmoset; Dopamine D4 receptor; Lurasidone; Object retrieval detour; Schizophrenia

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; ARIPIPRAZOLE; ASENAPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR; HALOPERIDOL; ILOPERIDONE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; RO105824; UNCLASSIFIED DRUG; 3 ((4 (4 CHLOROPHENYL)PIPERAZIN 1 YL)METHYL) 1H PYRROLO(2,3 B)PYRIDINE; 3-((4-(4-CHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-1H-PYRROLO(2,3-B)PYRIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; ISOINDOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; RO 10 5824; RO 10-5824; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CALLITRICHINAE; CHOLINERGIC RECEPTOR BLOCKING; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SINGLE DRUG DOSE; TASK PERFORMANCE; ANIMAL; CALLITHRIX; DOPAMINE D(4) RECEPTOR; DOSE RESPONSE; DRUG EFFECT; INSTRUMENTAL CONDITIONING; METABOLISM; OBJECT RETRIEVAL DETOUR; PROTEIN BINDING; RECALL; SCHIZOPHRENIA;

COGNITION; COMMON MARMOSET; DOPAMINE D(4) RECEPTOR; LURASIDONE; OBJECT RETRIEVAL DETOUR; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CALLITHRIX; COGNITION; CONDITIONING, OPERANT; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; ISOINDOLES; MALE; MENTAL RECALL; PROTEIN BINDING; PYRIDINES; PYRIMIDINES; PYRROLES; RECEPTORS, DOPAMINE D4; THIAZOLES;

EID: 84891113031     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.11.036     Document Type: Article

References (41)

1. Sharma T., Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003, 26:25-40.
2. Van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
3. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004, 56:301-307.
4. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 2004, 65:361-372.
5. Brown V.J., Bowman E.M. Rodent models of prefrontal cortical function. Trends Neurosci 2002, 25:340-343.
6. Uylings H.B., Groenewegen H.J., Kolb B. Do rats have a prefrontal cortex. Behav Brain Res 2003, 146:3-17.
7. Newman J.D., Kenkel W.M., Aronoff E.C., Bock N.A., Zametkin M.R., Silva A.C. A combined histological and MRI brain atlas of the common marmoset monkey, Callithrix jacchus. Brain Res Rev 2009, 62:1-18.
8. Diamond A., Zola-Morgan S., Squire L.R. Successful performance by monkeys with lesions of the hippocampal formation on AB and object retrieval, two tasks that mark developmental changes in human infants. Behav Neurosci 1989, 103:526-537.
9. Wilkinson L.S., Dias R., Thomas K.L., Augood S.J., Everitt B.J., Robbins T.W., et al. Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response to d-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys. Neuroscience 1997, 80:717-730.
10. Wallis J.D., Dias R., Robbins T.W., Roberts A.C. Dissociable contributions of the orbitofrontal and lateral prefrontal cortex of the marmoset to performance on a detour reaching task. Eur J Neurosci 2001, 13:1797-1808.
11. Jentsch J.D., Redmond D.E., Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 1997, 277:953-955.
12. Jentsch J.D., Taylor J.R., Redmond D.E., Elsworth J.D., Youngren K.D., Roth R.H. Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology (Berl) 1999, 142:78-84.
13. Rutten K., Basile J.L., Prickaerts J., Blokland A., Vivian J.A. Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology (Berl) 2008, 196:643-648.
14. Ballard T.M., Knoflach F., Prinssen E., Borroni E., Vivian J.A., Basile J., et al. RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors. Psychopharmacology (Berl) 2009, 202:207-223.
15. Murai T., Nakako T., Ikejiri M., Ishiyama T., Taiji M., Ikeda K. Effects of lurasidone on executive function in common marmosets. Behav Brain Res 2013, 246:125-131.
16. Ishiyama T., Loebel A., Cucchiaro J., Horisawa T., Tokuda K., Ogasa M., et al. Comparative receptor binding profile of lurasidone and other first and second generation antipsychotics. 27th World Congr CINP 2010 2010, [Abst P-20.038].
17. Millan M.J., Brocco M., Gobert A., Schreiber R., Dekeyne A. S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 1999, 288(3):1002-1014.
18. Shahid M., Wong E.H.F. Asenapine has a unique human receptor binding signature. Eur Neuropsychopharmacol 2005, 15(Suppl. 3). Abst P.3.136.
19. 2 receptor ligands using aripiprazole as the lead compound. Bioorg Med Chem 2011, 19:3502-3511.
20. Kongsamut S., Roehr J.E., Cai J., Hartman H.B., Weissensee P., Kerman L.L., et al. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 1996, 317:417-423.
21. Van Tol H.H.M., Bunzow J.R., Guan H.C., Sunahara R.K., Seeman P., Niznik H.B., et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991, 350:610-614.
22. Seeman P., Guan H.C., Van Tol H.H. Dopamine D4 receptors elevated in schizophrenia. Nature 1993, 365:441-445.
23. Murray A.M., Hyde T.M., Knable M.B., Herman M.M., Bigelow L.B., Carter J.M., et al. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 1995, 15:2186-2191.
24. Kramer M.S., Last B., Getson A., Reines S.A. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch Gen Psychiatry 1997, 54:567-572.
25. Corrigan M.H., Gallen C.C., Bonura M.L., Merchant K.M. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. Biol Psychiatry 2004, 55:445-451.
26. Bernaerts P., Tirelli E. Facilitatory effect of the dopamine D4 receptor agonist PD168,077 on memory consolidation of an inhibitory avoidance learned response in C57BL/6J mice. Behav Brain Res 2003, 142:41-52.
27. Woolley M.L., Waters K.A., Reavill C., Bull S., Lacroix L.P., Martyn A.J., et al. Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat. Behav Pharmacol 2008, 19:765-776.
28. Young J.W., Powell S.B., Scott C.N., Zhou X., Geyer M.A. The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: separating response inhibition from premature responding. Behav Brain Res 2011, 222:183-192.
29. Sood P., Idris N.F., Cole S., Grayson B., Neill J.C., Young A.M. PD168077, a D(4) receptor agonist, reverses object recognition deficits in rats: potential role for D(4) receptor mechanisms in improving cognitive dysfunction in schizophrenia. J Psychopharmacol 2011, 25:792-800.
30. Lanau F., Zenner M.T., Civelli O., Hartman D.S. Epinephrine and norepinephrine act as potent agonists at the recombinant human dopamine D4 receptor. J Neurochem 1997, 68:804-812.
31. Newman-Tancredi A., Audinot-Bouchez V., Gobert A., Millan M.J. Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors. Eur J Pharmacol 1997, 319:379-383.
32. Matsumoto M., Hidaka K., Tada S., Tasaki Y., Yamaguchi T. Polymorphic tandem repeats in dopamine D4 receptor are spread over primate species. Biochem Biophys Res Commun 1995, 207:467-475.
33. Tallman J.F., Primus R.J., Brodbeck R., Cornfield L., Meade R., Woodruff K., et al. I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther 1997, 282:1011-1019.
34. Millan M.J., Newman-Tancredi A., Brocco M., Gobert A., Lejeune F., Audinot V., et al. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride. J Pharmacol Exp Ther 1998, 287:167-186.
35. Powell S.B., Paulus M.P., Hartman D.S., Godel T., Geyer M.A. RO-10-5824 is a selective dopamine D4 receptor agonist that increases novel object exploration in C57 mice. Neuropharmacology 2003, 44:473-481.
36. Huang M., Horiguchi M., Felix A.R., Meltzer H.Y. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport 2012, 23:436-440.
37. Borroto-Escuela D.O., Van Craenenbroeck K., Romero-Fernandez W., Guidolin D., Woods A.S., Rivera A., et al. Dopamine D2 and D4 receptor heteromerization and its allosteric receptor-receptor interactions. Biochem Biophys Res Commun 2011, 404:928-934.
38. Kamei C., Chung Y.H., Tasaka K. Influence of certain H1-blockers on the step-through active avoidance response in rats. Psychopharmacology (Berl) 1990, 102(3):312-318.
39. Mori K., Yamashita H., Nagao M., Horiguchi J., Yamawaki S. Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients. Pharmacopsychiatry 2002, 35(1):6-11.
40. Horisawa T., Ishibashi T., Nishikawa H., Enomoto T., Toma S., Ishiyama T., et al. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res 2011, 220:83-906.
41. Horiguchi M., Huang M., Meltzer H.Y. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 2011, 338:605-614.